Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05564845
Other study ID # MEC-25022-0004
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 20, 2022
Est. completion date July 1, 2025

Study information

Verified date September 2022
Source Erasmus Medical Center
Contact Aida Kidane
Phone +3110-7036691
Email a.kidanegebremeskel@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Sickle cell disease (SCD) is an autosomal recessive red blood cell blood disorder. One especially vital organ affected in SCD is the brain. Individuals with SCD have an increased risk of both overt cerebral infarctions and silent infarctions. The latter are brain lesions without apparent neurological sequelae. Since cortical neurons in the brain lack the ability to regenerate, tissue damage accumulates throughout the already shortened lifespan of individuals with SCD, resulting in far-reaching consequences such as significant cognitive impairment. Currently, only hematological stem cell transplantation can halt the multiorgan tissue damage. However, the criteria to determine the timing of curative therapy do not center the brain, despite that subtle anomalies of this critical organ can have long-lasting consequences. Since it is not yet known whether brain tissue damage precedes, parallels, or lags behind non-brain tissue damage, it is critical to map these effects in youth with SCD. While importantly comparing images with a healthy reference population. Understanding how the brain is affected is critical for clinical decision making, such as timing of potentially curative interventions but also, to prevent long term irreversible brain damage in youth with SCD. In this study, a cohort of 84 SCD patients between the ages of 6 and 18 at baseline, will undergo MR imaging, neurological examination, neuropsychological assessment and blood sampling three times in total, with intervals of two years; results will be innovatively compared with children included in the Generation R population study (±8000 MRIs children and (young)adults) 6-20 years of age). Our hypothesis, based on the inability of the brain to generate new cortical neurons following cell death, is that brain function is impaired earlier than other organ systems and that there is an age-dependent limit in the brain's ability to remodel itself based on neuroplasticity.


Description:

Objective: The primary objective is to evaluate longitudinal developmental changes in brain structure in patients aged 6-18 years with SCD. The secondary objective is to analyze the longitudinal relations between biomarkers, demographic characteristics, brain structure, neurocognitive functioning, behavioral functioning and developmental changes in brain structure. Study Design: Longitudinal cohort study (BRICK) with a duration of 4 years. Study population: Children and adolescents with sickle cell disease (SCD) of all genotypes (e.g. HbSS, HbSβº, HbSβ+, and HbSC) aged 6 -18 years. This will be compared to a cohort of healthy children and adolescents from Generation R. Primary study endpoint: - Total white matter volume increase in children and adolescents with SCD Secondary study endpoints - Neurocognitive functioning (intelligence, specific neurocognitive functions, network organization) - Incidence of stroke - Other forms complications due to SCD - Amount of hospital admissions, day care admissions (adult care only), crises at home, contact moments with the sickle cell center, ER visits - Biomarkers for anemia, hemolysis, inflammation and endothelial activation. - Behavioral functioning Nature and extent of the burden and risk associated with participation, benefit and group relatedness: By creating an advanced model for structural neurological, neurocognitive functioning in SCD, we will gain more insight into the pathophysiological origins and risk factors for SCD-related brain abnormalities. This will support development of preventive and supportive strategies as well as the initiation and evaluation of therapeutic interventions. Previous experience with the performance of brain MRI scans combined with recent research, indicates that the emotional burden placed on young children when undergoing a brain MR scan, are proportionate to the emotional burden placed on adults when they undergo a brain MR-scan. Furthermore, children will be offered the opportunity to become acquainted with the research procedure by witnessing an MRI scan session prior before participation.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date July 1, 2025
Est. primary completion date July 1, 2025
Accepts healthy volunteers
Gender All
Age group 6 Years to 25 Years
Eligibility Inclusion Criteria: - Patients with SCD of all genotype between 6 and 18 at baseline Exclusion Criteria: - Parents/ guardians (in case of minors) or patients themselves (>16 years) unable to make an informed decision on participating in this study. - An abnormal brain MRI prior to initiation of the study due to non-SCD related causes. - Contraindications for brain MRI per protocol

Study Design


Intervention

Diagnostic Test:
MR scan of the brain
Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
Blood work
Lab work for current lab values and biobanking
Neurological examination
Classical neurological examination
Neuropsychological assessment
Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA) A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II) Narrative memory Word fluency Route finding NEPSY-II World Fluency Additional Questionnaires (6-18 years): Child Behavior Checklist (CBCL) Teacher Report Form (TRF) Youth Self Report (YSR) Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report) Conners-3® • Additional Questionnaires (18+ years): Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ<70) Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ<70) Conners' Adult ADHD Rating Scales (CAARS) Emma toolbox

Locations

Country Name City State
Netherlands Amsterdam University Medical Center Amsterdam
Netherlands Erasmus MC Rotterdam South Holland

Sponsors (2)

Lead Sponsor Collaborator
Dr. Marjon H. Cnossen MD PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary mm3/time unit Total white matter volume increase in children and adolescents with SCD 4 years
Secondary Full scale IQ (FSIQ) Neurocognitive functioning (intelligence, specific neurocognitive functions, network organization) 4 years
Secondary Incidence of stroke 4 years
Secondary Other forms complications due to SCD 4 years
Secondary Amount of hospital admissions 4 years
Secondary Ld, bilirubin Hemolysis biomarkers 4 years
Secondary Times/year ER visits 4 years
Secondary Hb, Ht Biomarkers for anemia 4 years
Secondary T score metric: a score of 50 represents the mean score of a reference population and 10 is the standard deviation. Patient-Reported Outcomes Measurement Information System® (PROMIS) within domains such as fatigue, pain behavior, depression, anxiety 4 years
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Not yet recruiting NCT06300723 - Clinical Study of BRL-101 in Severe SCD N/A
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Not yet recruiting NCT02525107 - Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements Phase 3
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1
Completed NCT02567695 - A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects Phase 1